These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. Meltzer HY J Clin Psychiatry; 2005 Apr; 66(4):530-3. PubMed ID: 15816797 [No Abstract] [Full Text] [Related]
3. Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial. Meltzer HY J Clin Psychiatry; 1999; 60 Suppl 12():47-50. PubMed ID: 10372612 [TBL] [Abstract][Full Text] [Related]
4. Suicide in schizophrenia: risk factors and clozapine treatment. Meltzer HY J Clin Psychiatry; 1998; 59 Suppl 3():15-20. PubMed ID: 9541333 [TBL] [Abstract][Full Text] [Related]
5. FDA's position on the clozaril patient management system. Peck CC Hosp Community Psychiatry; 1990 Aug; 41(8):876-7. PubMed ID: 2401475 [No Abstract] [Full Text] [Related]
7. [Hematologic effects of clozapine: evaluation of the international experience]. Lamarque V Encephale; 1995 Jun; 21 Spec No 3():59-60. PubMed ID: 7628344 [TBL] [Abstract][Full Text] [Related]
8. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Honigfeld G Psychiatr Serv; 1996 Jan; 47(1):52-6. PubMed ID: 8925346 [TBL] [Abstract][Full Text] [Related]
14. Notes from a state mental health directors' meeting on clozapine. Salzman C Hosp Community Psychiatry; 1990 Aug; 41(8):838-9, 842. PubMed ID: 2401474 [No Abstract] [Full Text] [Related]